Bone Biologics (NASDAQ:BBLG) Trading Up 1.4% – Here’s What Happened

Bone Biologics Corp. (NASDAQ:BBLG) was up 1.4% on Tuesday . The stock traded as high as $1.3950 and last traded at $1.40. Approximately 4,281 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 11,622 shares. The stock had previously closed at $1.38.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Bone Biologics has an average rating of “Sell”.

Bone Biologics Stock Down 4.3%

The firm has a market cap of $2.42 million, a PE ratio of -0.36 and a beta of 0.72. The firm has a 50-day moving average price of $1.22 and a two-hundred day moving average price of $1.62.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.34) EPS for the quarter, hitting analysts’ consensus estimates of ($0.34). Research analysts forecast that Bone Biologics Corp. will post -1.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its stake in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. 34.30% of the stock is owned by hedge funds and other institutional investors.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.